1
|
Lahire S, Fichel C, Rubaszewski O, Lerévérend C, Audonnet S, Visneux V, Perotin JM, Deslée G, Le Jan S, Potteaux S, Le Naour R, Pommier A. Elastin-derived peptides favor type 2 innate lymphoid cells in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2024; 326:L812-L820. [PMID: 38712445 DOI: 10.1152/ajplung.00306.2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 03/22/2024] [Accepted: 04/22/2024] [Indexed: 05/08/2024] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is a condition characterized by chronic airway inflammation and obstruction, primarily caused by tobacco smoking. Although the involvement of immune cells in COPD pathogenesis is well established, the contribution of innate lymphoid cells (ILCs) remains poorly understood. ILCs are a type of innate immune cells that participate in tissue remodeling processes, but their specific role in COPD has not been fully elucidated. During COPD, the breakdown of pulmonary elastin generates elastin peptides that elicit biological activities on immune cells. This study aimed to investigate the presence of ILC in patients with COPD and examine the impact of elastin peptides on their functionality. Our findings revealed an elevated proportion of ILC2 in the peripheral blood of patients with COPD, and a general activation of ILC as indicated by an increase in their cytokine secretion capacity. Notably, our study demonstrated that serum from patients with COPD promotes ILC2 phenotype, likely due to the elevated concentration of IL-5, a cytokine known to favor ILC2 activation. Furthermore, we uncovered that this increase in IL-5 secretion is partially attributed to its secretion by macrophages upon stimulation by elastin peptides, suggesting an indirect role of elastin peptides on ILC in COPD. These findings shed light on the involvement of ILC in COPD and provide insights into the potential interplay between elastin breakdown, immune cells, and disease progression. Further understanding of the mechanisms underlying ILC activation and their interaction with elastin peptides could contribute to the development of novel therapeutic strategies for COPD management.NEW & NOTEWORTHY Elastin-derived peptides, generated following alveolar degradation during emphysema in patients with COPD, are able to influence the response of type 2 innate lymphoid cells. We show that the orientation of innate lymphoid cells in patients with COPD is shifted toward a type 2 profile and that elastin peptides are indirectly participating in that shift through their influence of macrophages, which in turn impact innate lymphoid cells.
Collapse
Affiliation(s)
- Sarah Lahire
- Université de Reims Champagne Ardenne, Immuno-Régulation dans les Maladies Auto-Immunes, Inflammatoires et le Cancer (IRMAIC), Reims, France
| | - Caroline Fichel
- Université de Reims Champagne Ardenne, Immuno-Régulation dans les Maladies Auto-Immunes, Inflammatoires et le Cancer (IRMAIC), Reims, France
| | - Océane Rubaszewski
- Université de Reims Champagne Ardenne, Immuno-Régulation dans les Maladies Auto-Immunes, Inflammatoires et le Cancer (IRMAIC), Reims, France
| | - Cédric Lerévérend
- Université de Reims Champagne Ardenne, Immuno-Régulation dans les Maladies Auto-Immunes, Inflammatoires et le Cancer (IRMAIC), Reims, France
- Institut Godinot, Unicancer, Reims, France
| | - Sandra Audonnet
- Université de Reims Champagne Ardenne, Plateforme de cytométrie en flux, URCACyt, Reims, France
| | - Vincent Visneux
- CHU de Reims, Service des maladies respiratoires, Reims, France
| | - Jeanne-Marie Perotin
- CHU de Reims, Service des maladies respiratoires, Reims, France
- Université de Reims Champagne Ardenne, Inserm UMR-S 1250 Pathologies Pulmonaires et Plasticité Cellulaire (P3Cell), Reims, France
| | - Gaëtan Deslée
- CHU de Reims, Service des maladies respiratoires, Reims, France
- Université de Reims Champagne Ardenne, Inserm UMR-S 1250 Pathologies Pulmonaires et Plasticité Cellulaire (P3Cell), Reims, France
| | - Sébastien Le Jan
- Université de Reims Champagne Ardenne, Immuno-Régulation dans les Maladies Auto-Immunes, Inflammatoires et le Cancer (IRMAIC), Reims, France
| | - Stéphane Potteaux
- Université de Reims Champagne Ardenne, Immuno-Régulation dans les Maladies Auto-Immunes, Inflammatoires et le Cancer (IRMAIC), Reims, France
- Institut Godinot, Unicancer, Reims, France
- Délégation régionale Inserm Paris Ile-de France Centre Nord, Paris, France
| | - Richard Le Naour
- Université de Reims Champagne Ardenne, Immuno-Régulation dans les Maladies Auto-Immunes, Inflammatoires et le Cancer (IRMAIC), Reims, France
| | - Arnaud Pommier
- Université de Reims Champagne Ardenne, Immuno-Régulation dans les Maladies Auto-Immunes, Inflammatoires et le Cancer (IRMAIC), Reims, France
| |
Collapse
|
2
|
Day de Larrañaga F, Joubert A, Drouin I, Ouellet I, Li PZ, Ross BA, Baglole CJ, Bourbeau J. Biological Anti-IL-5/IL-5R Therapeutics for Chronic Obstructive Pulmonary Disease (COPD) with Specific Treatable Traits: A Real-World Retrospective Analysis. Int J Chron Obstruct Pulmon Dis 2024; 19:217-223. [PMID: 38249820 PMCID: PMC10800109 DOI: 10.2147/copd.s438153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Accepted: 01/07/2024] [Indexed: 01/23/2024] Open
Abstract
Introduction We describe the use of anti-IL-5 monoclonal antibodies from a COPD clinic, a source other than traditional clinical trials. The objectives were to characterize the patient subgroup prescribed anti-IL-5 monoclonal antibodies and to report potential benefits. Methods This is a retrospective case series study of 17 patients treated in a COPD subspecialty clinic. All patients had a diagnosis of COPD (post-bronchodilator FEV1/FVC <0.7) and had been prescribed an anti-IL-5 biologic for at least 8 months. Acute exacerbations of COPD (AECOPDs) were collected as reported in electronic medical records. Results All patients (17) enrolled were treated with biologics for ≥8 months, and 13 (76%) for ≥1 year. Patients were characterized by severe disease traits, FEV1 <50% predicted, recurrent exacerbations (3.5 moderate-to-severe AECOPDs in the year before treatment), high peripheral blood eosinophil counts (≥250 cells/μL in the previous year), all on inhaled triple therapy, and only 1 patient with a diagnosis of asthma prior to smoking. There was a statistically significant decrease in the exacerbation rate compared with baseline after 8 and 12 months of anti-IL-5 treatment, respectively, yielding the equivalent of a 2-3x reduction in exacerbation rate. Absolute FEV1 decreased, and the decline in FEV1 % of predicted reached statistical significance (p<0.05); CAT score improved (p<0.05). Discussion This real-world evidence data aligns with existing studies suggesting the potential benefit of anti-IL-5 treatment for specific patients with COPD and therefore advocates for further investigation of RCTs on the use of anti-IL-5 biologics for well-characterized patients with COPD.
Collapse
Affiliation(s)
- Forest Day de Larrañaga
- Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
- Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
| | - Alexandre Joubert
- COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada
| | - Isabelle Drouin
- COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada
| | - Isabelle Ouellet
- COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada
| | - Pei Zhi Li
- Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
| | - Bryan A Ross
- Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
- Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
- COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada
| | - Carolyn J Baglole
- Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
- Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
| | - Jean Bourbeau
- Research Institute of McGill University Health Centre, Montreal, Quebec, Canada
- Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada
- COPD Clinic, McGill University Health Centre, Montreal, Quebec, Canada
| |
Collapse
|